CDK
CDK (Cyclin-Dependent Kinase) inhibitors are compounds that block the activity of CDKs, a group of protein kinases that regulate the cell cycle, transcription, and other cellular processes. CDKs are activated by binding to cyclins, and their activity is crucial for the progression of cells through different phases of the cell cycle. Inhibiting CDKs can halt cell division, leading to cell cycle arrest and apoptosis, particularly in cancer cells where CDKs are often dysregulated. CDK inhibitors are widely used in cancer research and have therapeutic potential in treating various cancers. At CymitQuimica, we provide a comprehensive selection of high-quality CDK inhibitors to support your research in cell cycle control, cancer, and therapeutic development.
Found 546 products of "CDK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
CDK8-IN-12
CAS:CDK8-IN-12: selective CDK8 inhibitor (Ki 14 nM), oral anticancer, blocks GSK-3α/β, PCK-θ, halts MV4-11 cell growth.Formula:C21H20ClN3O2Purity:98.55% - 99.22%Color and Shape:SoildMolecular weight:381.86Ref: TM-T72048
1mg52.00€5mg101.00€10mg150.00€25mg250.00€50mg363.00€100mg509.00€200mg695.00€1mL*10mM (DMSO)116.00€TMX-2138
CAS:TMX-2138 is a CDKs PROTAC degrader, with IC50 values of 8.7 nM for CDK1/cyclinB, 10.9 nM for CDK2/cyclinA, 7.0 nM for CDK5/p25, and 25.7 nM for CDK9/cyclinT1. It enhances the ubiquitination and degradation of CDKs and is utilized for ovarian cancer research.Formula:C40H43BrFN9O11SColor and Shape:SolidMolecular weight:956.791LL-K8-22
LL-K8-22: potent CDK8/cyclin C degrader; DC50 ~2.5μM; hinders STAT1 phosphorylation; curbs E2F/MYC cancer pathways; for TNBC study.Formula:C37H43N5OColor and Shape:SolidMolecular weight:573.77FDA-Approved Kinase Inhibitor Library
A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.
Color and Shape:LiquidKinase Inhibitor Library
A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;Color and Shape:Odour SolidRef: TM-L1600
1mgTo inquire30μL*10mM (DMSO)To inquire50μL*10mM (DMSO)To inquire100μL*10mM (DMSO)To inquire250μL*10mM (DMSO)To inquireXY028-133
CAS:XY028-133 is a PROTAC-based CDK4/6 degrader for the study of tumors.
Formula:C53H67N11O7SPurity:97.11%Color and Shape:SolidMolecular weight:1002.23CDK4/6-IN-11
CAS:CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader.Formula:C43H49N11O7Color and Shape:SolidMolecular weight:831.92PROTAC CDK9 degrader 4
CAS:PROTAC CDK9 degrader 4 is a CDK9 degrader that targets transcriptional regulation and has potential anticancer activity.Formula:C43H56N10O5Color and Shape:SolidMolecular weight:792.97CDK4/6-IN-23
CDK4/6-IN-23 (Compound 42) is a potent and selective inhibitor of CDK4/6, displaying an IC50 of 11 nM for CDK6. This compound significantly activates immune cells and enhances IL-3 production. In mice undergoing 5-FU chemotherapy, CDK4/6-IN-23 demonstrates dual bone marrow protection and immunomodulatory effects.Formula:C32H34FN7O4Color and Shape:SolidMolecular weight:599.655WAY-322243
CAS:WAY-322243 has antibacterial and anti-inflammatory activity and has an inhibitory effect on CLK-1, which can be used to study Alzheimer's disease.Formula:C18H18N2O2SPurity:99.88%Color and Shape:SoildMolecular weight:326.41MeBIO
CAS:MeBIO is an agonist of aryl hydrocarbon receptor, with IC50 of 44 and 55 μM for GSK-3 and CDK1/CyclinB, respectively. MeBIO does not affect GSK-3β.Formula:C17H12BrN3O2Purity:99.64%Color and Shape:SolidMolecular weight:370.2Ref: TM-T21966
1mg39.00€5mg74.00€10mg117.00€25mg220.00€50mg354.00€100mg520.00€500mg1,130.00€1mL*10mM (DMSO)86.00€CDK1-IN-2
CAS:CDK1-IN-2 (cdk1 inhibitor 2) is a CDK1 inhibitor with IC50 of 5.8 μM.Formula:C17H11ClN2OPurity:98.53%Color and Shape:SoildMolecular weight:294.73Ref: TM-T64373
1mg50.00€5mg107.00€10mg170.00€25mg354.00€50mg567.00€100mg810.00€500mg1,644.00€1mL*10mM (DMSO)103.00€Cell Cycle Compound Library
A unique collection of xnum cell cycle related compounds for high throughput screening (HTS) and high content screening (HCS);
Color and Shape:Odour SolidCDK4/6-IN-5
CAS:CDK4/6-IN-5 inhibits CDK4/6; Ki: 0.2 nM (CDK4/D1) & 4.4 nM (CDK6/D3). (WO2019207463A1, A93)Formula:C22H28ClFN6O4SColor and Shape:SolidMolecular weight:527.01CDK12-IN-2
CAS:CDK12-IN-2 selectively inhibits CDK12 (IC50: 52 nM) with minimal effect on CDK2, CDK7, and CDK9, useful for CDK12 research.
Formula:C32H32N6O2Purity:99.31%Color and Shape:SolidMolecular weight:532.64CDK-IN-12
CAS:CDK-IN-12 (Example 20), a CDK inhibitor, effectively inhibits CDK4/6, demonstrating IC50 values below 20 nM [1].Formula:C26H29FN6OSColor and Shape:SolidMolecular weight:492.61JH-XVI-178
CAS:JH-XVI-178: potent CDK8/19 inhibitor with good pharmacokinetics, low clearance, moderate oral bioavailability.Formula:C22H22ClN7OColor and Shape:SolidMolecular weight:435.92HTH-01-091 TFA
HTH-01-091 TFA: Potent, selective MELK inhibitor (IC50=10.5 nM); also targets PIM1/2/3, RIPK2, DYRK3, smMLCK, CLK2; used in breast cancer research.Formula:C28H29Cl2F3N4O4Color and Shape:SolidMolecular weight:613.46PROTAC CDK9 degrader-6
CAS:PROTAC CDK9 degrader-6 targets and degrades CDK9 isoforms via proteasome, with DC50 of 0.10μM and 0.14μM.Formula:C42H49Cl2N9O8Purity:98%Color and Shape:SolidMolecular weight:878.8CDK9-IN-26
CDK9-IN-26, also known as compound 1, is a potent inhibitor of Cyclin-Dependent Kinase 9 (CDK9) with an IC50 value of 0.18 μM.[1]Formula:C17H14N4O2Purity:98%Color and Shape:SolidMolecular weight:306.32
